Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
Sponsor: InSilico Medicine Hong Kong Limited
Summary
The purpose of this revised Phase IIa study is to demonstrate safety of INS018\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).
Official title: A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Key Details
Gender
All
Age Range
40 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-02-08
Completion Date
2026-02-28
Last Updated
2025-11-12
Healthy Volunteers
No
Conditions
Interventions
INS018_055
Pharmaceutical formulation: Tablet Mode of Administration: Oral
Placebo
Pharmaceutical formulation: Tablet Mode of Administration: Oral
Locations (12)
University of Alabama at Birmingham
Birmingham, Alabama, United States
HonorHealth Research Institute
Scottsdale, Arizona, United States
Keck School of Medicine of USC
Los Angeles, California, United States
Florida Lung Asthma and Sleep Specialist
Celebration, Florida, United States
Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando
Orlando, Florida, United States
Southeastern Research Center
Winston-Salem, North Carolina, United States
University of Oklahoma Health Sciences Center (OUHSC)
Oklahoma City, Oklahoma, United States
Temple University Hospital-Temple Lung Center
Philadelphia, Pennsylvania, United States
Bogan Sleep Consultants, LLC
Columbia, South Carolina, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Metroplex Pulmonary and Sleep Center
McKinney, Texas, United States
Research Centers of America
McKinney, Texas, United States